debt_leverage_profile
Minimal debt; MaxCyte holds ~$200M+ cash with negligible long-term debt, so a 20% rate rise has near-zero interest expense impact
Inferred
Agent_Inference
interest_rate_sensitivity
Net cash position means rising rates are mildly beneficial; higher yields on cash holdings offset any minor floating-rate exposure
Inferred
Agent_Inference
geopolitical_supply_exposure
Medium intensity; US-China trade tariffs on metals and components disrupt supply chains.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Semiconductor/microelectronics from Taiwan (electroporation hardware components) and specialty consumables from European single-source suppliers
Inferred
Agent_Inference
international_expansion_readiness
EU (EUR), UK (GBP), Japan (JPY) are top international markets; JPY and GBP devaluation pose moderate revenue translation risk given ~30-40% international mix
Inferred
Agent_Inference
geographic_footprint
Primarily US-based revenue (~60%); significant EU exposure; Japan and Asia-Pacific growing; currency translation risk moderate but not existential
Inferred
Agent_Inference
commodity_exposure_profile
Medium intensity; commodities: Steel, Aluminum, Copper, Crude Oil (fuel), Rare Earth Elements, Plastics/Resins; geopolitical: US-China trade tariffs on metals and components disrupt supply chains.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single-source risk on specialized flow-electroporation components; no single vendor >30% of total cost, but hardware BOM has limited substitutes
Inferred
Agent_Inference
business_model_type_primary
Instrument/platform plus recurring consumables and licensing; not cloud-dependent — termination of AWS/GCP would disrupt data/SaaS tools but not core revenue
Inferred
Agent_Inference
business_model_type_secondary
SPE licensing (Strategic Platform Agreements) provides high-margin recurring royalty stream tied to cell therapy commercialization milestones
Inferred
Agent_Inference
switching_cost_profile
Very high API/platform coupling; customers integrate MaxCyte instruments deeply into GMP manufacturing workflows — switching costs are regulatory, operational, and capital-intensive
Inferred
Agent_Inference
howey_test_risk_index
Not applicable; MaxCyte sells instruments, consumables, and IP licenses — no securities-like revenue instrument; Howey Test risk is negligible
Inferred
Agent_Inference
regulatory_burden_tier
Medium
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure via EU clinical/research customer data; CCPA exposure limited; company is not a primary data processor but must maintain compliant data-handling agreements
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche electroporation market with Lonza and Miltenyi as competitors; market share not dominant enough to trigger regulatory scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Medium burden; regimes: FAA, DOT, OSHA, EPA, ITAR, FTC; Export controls and defense procurement rules create contract concentration risk.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Recurring ~60-65% (SPE licensing, consumables under multi-year agreements); transactional ~35-40% (instrument sales, milestone payments)
Inferred
Agent_Inference
monetization_vector
Razor-and-blade plus IP licensing royalties; instruments drive consumable pull-through; SPE agreements capture upside from customer commercial success
Inferred
Agent_Inference
pricing_architecture
Premium pricing supported by regulatory lock-in and GMP validation; vulnerable if biosimilar/generic cell therapy wave compresses customer margins long-term
Inferred
Agent_Inference
pricing_power_rating
High (8/10); GMP-validated, FDA-referenced platform creates strong pricing moat; customers cannot reprice mid-clinical-trial without revalidation costs
Inferred
Agent_Inference
target_gross_margin_bracket
127.9% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
Minimal free-rider risk; proprietary consumables and instrument access require active licensing — no open-source alternative path exists currently
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth model; consumables and licensing scale without proportional headcount addition; R&D and field support modestly linear but overall leverage improves at scale
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of incremental licensing revenue near zero; consumables manufacturing has modest variable cost; doubling revenue would require ~30-40% headcount increase, not 100%
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; MaxCyte does not operate a franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely improves significantly via reference network effects in cell therapy; LTV/CAC ratio already favorable given multi-decade SPE contract structures
Inferred
Agent_Inference
network_effect_present
Weak direct network effect; strong indirect effect — more clinical successes using MaxCyte create industry-standard reference, increasing next-customer adoption probability
Inferred
Agent_Inference
asset_efficiency_ratio
-22.0% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 2 (moderate resilience); clinical-stage biotech funding is recession-sensitive, but large pharma SPE partners provide stable revenue floor; capital equipment sales vulnerable
Inferred
Agent_Inference
customer_segment_primary
Large pharmaceutical and biotech companies developing cell therapies (CAR-T, TCR, gene editing); top 5 customers likely represent 40-50% of revenue
Inferred
Agent_Inference
customer_segment_secondary
Academic and government research institutions; smaller biotech startups in cell and gene therapy; more transactional, lower contract value, higher churn risk
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "23-0000 Legal Occupations", "33-0000 Protective Service Occupations", "37-0000 Building and Grounds Cleaning and Maintenance Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "47-0000 Construction and Extraction Occupations", "49-0000 Installation, Maintenance, and Repair Occupations", "51-0000 Production Occupations", "53-0000 Transportation and Material Moving Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.3 (HIL — ~30% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
8.4% CapEx / Revenue (Moderate-CapEx)
High
SEC-XBRL
sec_cik
0001287098
High
SEC-EDGAR
ticker
MXCT
High
SEC-EDGAR